

# Impact of obstructive sleep apnea diagnosis on healthcare resource utilization in patients with obstructive lung disease

**First published:** 25/07/2017

**Last updated:** 08/08/2024

Study

Finalised

## Administrative details

### EU PAS number

EUPAS19984

---

### Study ID

31027


---

### DARWIN EU® study

No

---

### Study countries

 United Kingdom

---

### Study description

A historical observational database study UK using primary care data to evaluate the frequency of continuous positive airway pressure (CPAP) therapy prescribing in patients with sleep-related breathing disorder (SBD, including obstructive sleep apnoea). The study will assess SBD patient characteristics (clinical and demographic) in those in whom CPAP treatment is recorded/coded (vs not recorded). Finally the study will evaluate the impact of (i) CPAP and (ii) a SBD diagnosis (as a proxy for CPAP treatment) and (iii) an OSA diagnosis on clinical outcomes and healthcare resource utilization in a representative SBD population of patients in the United Kingdom with comorbid obstructive lung disease.

---










### **Study status**


Finalised


## Research institutions and networks

### Networks

#### Respiratory Effectiveness Group (REG)

-  Belgium
-  Denmark
-  France
-  Germany
-  Greece
-  Hungary
-  Italy
-  Netherlands
-  Spain

 Sweden

 United Kingdom

**First published:** 07/07/2021

**Last updated:** 04/06/2024

Network

ENCePP partner

## Contact details

### Study institution contact

Sarah Lucas [sarah@REGresearchnetwork.org](mailto:sarah@REGresearchnetwork.org)

Study contact

[sarah@REGresearchnetwork.org](mailto:sarah@REGresearchnetwork.org)

### Primary lead investigator

Michaela Stefan

Primary lead investigator

## Study timelines

### Date when funding contract was signed

Planned: 16/12/2016

Actual: 16/12/2016

---

### Study start date

Planned: 01/12/2017

Actual: 01/06/2018

---

### **Data analysis start date**

Planned: 01/02/2018

---

### **Date of final study report**

Planned: 30/09/2018

Actual: 30/09/2018

## Sources of funding

- Other

## More details on funding

Respiratory Effectiveness Group

## Study protocol

[OSA and Comorbid OLD\\_Pilot Study Protocol\\_REG.pdf](#) (2.01 MB)

## Regulatory

### **Was the study required by a regulatory body?**

No

---

### **Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

### Study type list

**Study topic:**

Disease /health condition

Other

---

**Study topic, other:**

Healthcare resource utilization

**Study type:**

Non-interventional study

---

**Scope of the study:**

Disease epidemiology

Healthcare resource utilisation

**Data collection methods:**

Secondary use of data

---

**Main study objective:**

To evaluate the impact of (i) CPAP and (ii) a SBD diagnosis and (iii) an OSA diagnosis on clinical outcomes and healthcare resource utilization in a representative SBD population of patients in the United Kingdom with comorbid obstructive lung disease.

## Study Design

**Non-interventional study design**

Cohort

Cross-sectional

## Study drug and medical condition

## **Medical condition to be studied**

Sleep apnoea syndrome

## **Population studied**

### **Short description of the study population**

Patients with sleep-related breathing disorder (SBD, including obstructive sleep apnoea).

Patients with following criteria were included:

1.  $\geq 18$  years of age
2. A physician diagnosis of SDB, defined as  $\geq 1$  SDB diagnostic codes

Additional criteria for Aim 3

- Three years of continuous data:  $\geq 1$  year prior to the first recorded SDB code (“index date”) and  $\geq 2$  years immediately after index date.
  - An active Obstructive Lung Disease (OLD):
    - o Asthma subpopulation: a Quality Outcomes Framework (QoF) Read code for asthma ever prior to index date,  $\geq 2$  asthma prescriptions in each of the baseline years; no COPD Read code in the 4-year study period
    - o COPD subpopulation: a QoF Read code for COPD prior to index date,  $\geq 2$  COPD prescriptions in each of the baseline years; no asthma Read code in the 4-year study period
- 

### **Age groups**

- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)

- Adults (75 to < 85 years)
  - Adults (85 years and over)
- 

### **Special population of interest**

Other

---

### **Special population of interest, other**

Sleep-related Breathing Disorders patients

---

### **Estimated number of subjects**

8500

## Study design details

### **Outcomes**

Acute respiratory event rate  
i) Hospital admissions  
ii) A&E attendance  
iii) Acute course of oral steroids  
iv) Antibiotic prescriptions, Overall healthcare cost-Total: Encounter + Drug related.

---

### **Data analysis plan**

Outcome comparison between pre- and post index date periods, for:  
i) All Active Patients  
ii) All Active OLD sub-populations (asthma, COPD, asthma & COPD)

## Data management

## ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

### Data source(s)

Optimum Patient Care Research Database

---

### Data sources (types)

[Electronic healthcare records \(EHR\)](#)

## Use of a Common Data Model (CDM)

### CDM mapping

No

## Data quality specifications

### Check conformance

Unknown

---

### Check completeness

Unknown

---

### Check stability

Unknown

---

## **Check logical consistency**

Unknown

# Data characterisation

## **Data characterisation conducted**

Unknown